Compare Ascendis Pharma A/S (ASND) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs KeyCorp — how do they compare? Ascendis Pharma A/S trades at $263.88 (market cap $17.74B), while KeyCorp trades at $23.15 (market cap $25.15B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 3.52% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KEY | |
|---|---|---|
Market Cap | $17.74B | $25.15B |
Sector | Health | Financials |
52-Week High | $277.18 | $23.43 |
52-Week Low | $163.32 | $16.78 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KeyCorp (KEY) trades at $23.30, up 0.87% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.42. Revenue rebounded to $7.29 billion in 2025, driving net income to $1.83 billion. Analyst consensus is strongly positive, with a $29.32 price target representing significant upside. Recent news highlights a new $3 billion share buyback program and innovations in business fraud protection.
The outlook for KEY is favorable, supported by earnings momentum, shareholder returns, and analyst optimism. Key opportunities include continued earnings beats and capital return initiatives. Risks involve volatile cash flows, with net cash flow negative in 2025 and 2026, and sensitivity to interest rate changes affecting bank profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
